Study Population. Subjects with postmenopausal osteoporosis who completed the End-of-Treatment Visit (Visit 9) for Study BA058-05-003 and were previously randomized to either blinded Abaloparatide-SC or blinded Placebo are eligible for inclusion into this Extension Study provided that they fulfill the Inclusion/Exclusion criteria described below.
Appears in 2 contracts
Samples: Trial Services Agreement (Radius Health, Inc.), Trial Services Agreement (Radius Health, Inc.)
Study Population. Subjects with postmenopausal osteoporosis who completed the End-of-Treatment Visit (Visit 9) for Study BA058-05-003 and were previously randomized to either blinded Abaloparatide-SC BA058 Injection 80 µg or blinded Placebo are eligible for inclusion into this Extension Study provided that they fulfill the Inclusion/Exclusion criteria described below.
Appears in 2 contracts
Samples: Clinical Trial Services Agreement (Radius Health, Inc.), Clinical Study Protocol (Radius Health, Inc.)
